Vertex Pharmaceuticals Incorporated
Acquisitions
3
Major Deals Covered
$15.8B
Disclosed Deal Value
Vertex Pharmaceuticals's largest disclosed acquisition here is Crinetics Pharmaceuticals for $10B in 2026. This page covers 3 major deals from 2019 to 2026, each with its price where disclosed and the reason behind it.
| Company | Year | Price | Purpose |
|---|---|---|---|
| Alpine Immune Sciences | 2024 | $4.9B | All-cash deal for Alpine and its lead drug povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune kidney diseases. |
| Semma Therapeutics | 2019 | $950.0M | Cash acquisition of a startup making insulin-producing islet cells from stem cells. |
| Crinetics Pharmaceuticals | 2026 | $10.0B | Adds rare endocrine diseases as a fifth focus area, with PALSONIFY (paltusotine) for acromegaly and atumelnant in Phase 3 for congenital adrenal hyperplasia. |
2026
$10.0B
Adds rare endocrine diseases as a fifth focus area, with PALSONIFY (paltusotine) for acromegaly and atumelnant in Phase 3 for congenital adrenal hyperplasia.
Announced July 6, 2026 and completed September 1, 2026 at a total equity value of about $10.0 billion (about $8.8 billion net of cash acquired).
Vertex expects the deal to become accretive to non-GAAP operating income in 2029.
2024
$4.9B
All-cash deal for Alpine and its lead drug povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune kidney diseases.
Gave Vertex a late-stage renal asset to pair with its in-house APOL1 kidney program.
Most of the purchase price was expensed as acquired in-process R&D, producing Vertex's 2024 GAAP net loss.
2019
$950M
Cash acquisition of a startup making insulin-producing islet cells from stem cells.
Provided the technology behind Vertex's type 1 diabetes cell therapy program, now zimislecel.
Moved Vertex beyond small molecules into cell therapy.
Vertex is pursuing growth through lifecycle management in cystic fibrosis, launches in genetic medicines and acute pain, heavy R&D spending, targeted partnerships, and selective acquisitions in validated disease areas. The strategy is conservative in one sense because the company avoids scattering capital across unrelated therapeutic categories, but aggressive in another because it is willing to fund first-in-class or operationally complex modalities when the biology is compelling.
Vertex earns almost all of its revenue from product sales of patented specialty medicines. Cystic fibrosis is the base: TRIKAFTA/KAFTRIO, the newer once-daily ALYFTREK, and older modulators such as KALYDECO, ORKAMBI, and SYMDEKO are sold to a relatively small, well-defined patient population at high per-patient prices that are negotiated with US payers and national health systems. Newer revenue comes from CASGEVY, the CRISPR-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia that Vertex co-owns with CRISPR Therapeutics and delivers through authorized treatment centers, from JOURNAVX (suzetrigine), a non-opioid pill for moderate-to-severe acute pain, and, since September 2026, from PALSONIFY for acromegaly, acquired with Crinetics. Cash flow from cystic fibrosis funds a large R&D budget and acquisitions such as Alpine Immune Sciences (2024) and Crinetics (2026).
In May 2024, Vertex completed its largest acquisition ever, purchasing Alpine Immune Sciences for $4.9 billion in cash ($65/share) to acquire povetacicept, a Phase 3 dual BAFF/APRIL antagonist for IgA nephropathy.
It established Vertex as a premier player in nephrology, pairing povetacicept with its internal Phase 3 APOL1-mediated kidney disease drug inaxaplin to create a dominant kidney disease franchise.
In September 2019, Vertex acquired Semma Therapeutics for $950 million in cash, gaining proprietary technology pioneered by Dr. Doug Melton to produce fully functional, insulin-producing islet cells for Type 1 Diabetes.
In July 2022, Vertex acquired ViaCyte for $320 million in cash, uniting ViaCyte's stem-cell lines, intellectual property, and proprietary encapsulation devices with Vertex's Semma diabetes platform.
In June 2019, Vertex acquired gene-editing startup Exonics Therapeutics for $245 million upfront (with milestones up to $1 billion), targeting Single-Cut CRISPR gene editing for Duchenne muscular dystrophy.
Beginning in 2015, Vertex invested hundreds of millions into research agreements with CRISPR Therapeutics, eventually licensing exclusive global rights to CASGEVY and paying a $900M upfront fee in 2021 to secure a 60/40 profit share.
Vertex rarely acquires commercial-stage companies; instead, it selectively acquires breakthrough clinical-stage biology platforms with validated human genetics that can produce transformative, first-in-class medicines.
In 2001, Vertex acquired Aurora Biosciences for $592 million in stock, gaining high-throughput cellular screening technology in San Diego that directly discovered Kalydeco and the cystic fibrosis modulators.
Vertex preserves specialized R&D sites (such as Semma's cell manufacturing facilities in Providence and Boston), integrating acquired scientists into Vertex's global drug discovery network.
Targets must offer curative or transformative therapeutic potential, clear causal human biology, addressable high-value specialty indications, and an unassailable intellectual property estate.
Vertex funds acquisitions entirely from accumulated free cash flow and cash reserves generated by its cystic fibrosis monopoly, maintaining a fortress balance sheet with zero net debt.
With over $10 billion in balance sheet liquidity, Vertex will continue pursuing opportunistic clinical-stage biotech acquisitions in precision genetic medicines, immunology, and targeted cell therapies.
Compare corporate acquisition records, deal values, and strategic targets
Explore Vertex Pharmaceuticals
Core profile pages, founders and related research hubs for this company.